We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Switch From Tenofovir to Raltegravir for Low Bone Mineral Density (TROP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00939874
Recruitment Status : Completed
First Posted : July 15, 2009
Results First Posted : June 12, 2015
Last Update Posted : June 12, 2015
Information provided by (Responsible Party):

July 14, 2009
July 15, 2009
January 13, 2015
June 12, 2015
June 12, 2015
October 2009
June 2012   (Final data collection date for primary outcome measure)
Percent Change in Bone Mineral Density (BMD) of Lumbar Spine and Hips [ Time Frame: from Baseline to Weeks 48 and 96 ]
Percent Change in Bone Mineral Density of Lumbar Spine and Hips from Baseline to Weeks 48 and 96
Bone Mineral Density [ Time Frame: over 48 weeks ]
Complete list of historical versions of study NCT00939874 on ClinicalTrials.gov Archive Site
Percentage of Participants With HIV Viral Load <50 Copies/mL [ Time Frame: from Baseline to Week 96 ]
Plasma HIV viral load remained <50 copies/mL
LFTS, urea, electrolytes, creatinine, VL and CD4 count, Bone alkaline phosphatase and osteocalcin, N-telopeptide [ Time Frame: over 48 weeks ]
Not Provided
Not Provided
Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
Switch From Tenofovir to Raltegravir for Low Bone Mineral Density

The purpose of this study is to determine if low bone mineral density (a measurement of how thick and strong bones are) improves in adults with HIV infection who switch their HIV medication tenofovir to another HIV medication raltegravir.

Hypothesis:That Bone Mineral Density (BMD) will improve in osteopenic or osteoporotic patients switching from ART including tenofovir disoproxil fumarate (TDF) and a ritonavir-boosted protease inhibitor (r/PI) to ART including RAL+r/PI.

Not Provided
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • HIV
  • Osteopenia
  • Osteoporosis
  • HIV Infections
Drug: Raltegravir
Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
Other Names:
  • Isentress
  • MK-0518
Experimental: Raltegravir
Intervention: Drug: Raltegravir
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
April 2014
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. provision of written, informed consent
  2. HIV-infected adults at least 18 years of age
  3. receiving stable ART including TDF and a r/PI for the previous 6 months
  4. no prior PI genotypic resistance or known replication of HIV in patients receiving a PI
  5. plasma HIV RNA < 50 copies/ml for at least the previous 3 months
  6. spine or neck of femur t-score ≤ -1.0 (i.e. WHO-defined osteopenia) measured by dual energy x-ray absorptiometry (DEXA)

    Exclusion Criteria:

  7. participation in any other clinical trial (unless approved by the study PI)
  8. use of TDF for previously active chronic hepatitis B infection
  9. receiving or requiring therapy for low BMD (including prior fragility fracture)
  10. using oral corticosteroids or inhaled fluticasone
  11. virological failure on, or intolerance to, RAL
  12. contra-indication to RAL therapy (see appendix 2)
  13. breast-feeding
  14. pregnancy
  15. secondary, endocrinological cause of low BMD:25-hydroxy vitamin D deficiency, hypogonadism: a)symptomatic b)asymptomatic defined by total testosterone > 25% below lower limit of reference range and/or luteinizing hormone > 2 x upper limit of normal (ULN),untreated hypothyroidism or hyperparathyroidism according to local reference ranges
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Andrew Carr, St Vincent's Hospital, Sydney
St Vincent's Hospital, Sydney
  • Merck Sharp & Dohme Corp.
  • Holdsworth House Medical Practice
  • The Alfred
Principal Investigator: Andrew D Carr, Professor St Vincents Hospital
St Vincent's Hospital, Sydney
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP